title: A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge.
abstract: It has been suggested that poor immunogenicity may explain the lack of vaccine efficacy in preventing or controlling HIV infection in the Step trial. To investigate this issue we vaccinated eight Indian rhesus macaques with a trivalent replication-incompetent adenovirus serotype 5 vaccine expressing SIV Gag, Pol, and Nef using a regimen similar to that employed in the Step trial. We detected broad vaccine-induced CD8(+) (2-7 pool-specific responses) and CD4(+) (5-19 pool-specific responses) T-cell responses in IFN-γ ELISPOT assays at one week post-boost using fresh PBMC. However, using cryopreserved cells at one and four weeks post-boost we observed a reduction in both the number and magnitude of most vaccine-induced responses. This demonstrates that the time points and conditions chosen to perform immune assays may influence the observed breadth and frequency of vaccine-induced T-cell responses. To evaluate protective efficacy, we challenged the immunized macaques, along with naïve controls, with repeated, limiting doses of the heterologous swarm isolate SIVsmE660. Vaccination did not significantly affect acquisition or control of virus replication in vaccinees compared to naïve controls. Post-infection we observed an average of only two anamnestic CD8(+) T-cell responses per animal, which may not have been sufficiently broad to control heterologous virus replication. While the trivalent vaccine regimen induced relatively broad T-cell responses in rhesus macaques, it failed to protect against infection or control viral replication. Our results are consistent with those observed in the Step trial and indicate that SIV immunization and challenge studies in macaque models of HIV infection can be informative in assessing pre-clinical HIV vaccines.
authors.affiliation: AIDS Vaccine Research Laboratory, 555 Science Drive, Madison, WI 53711, USA. mrreynol@wisc.edu
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Reynolds
authors.forename: Andrea M
authors.initials: AM
authors.lastname: Weiler
authors.forename: Shari M
authors.initials: SM
authors.lastname: Piaskowski
authors.forename: Michael
authors.initials: M
authors.lastname: Piatak
authors.forename: Henry T
authors.initials: HT
authors.lastname: Robertson
authors.forename: David B
authors.initials: DB
authors.lastname: Allison
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Bett
authors.forename: Danilo R
authors.initials: DR
authors.lastname: Casimiro
authors.forename: John W
authors.initials: JW
authors.lastname: Shiver
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Wilson
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Lifson
authors.forename: Wayne C
authors.initials: WC
authors.lastname: Koff
authors.forename: David I
authors.initials: DI
authors.lastname: Watkins
mesh_terms: D000256:Adenoviridae / Q000276:immunology; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D015683:Gene Products, gag / Q000276:immunology; D015693:Gene Products, nef / Q000276:immunology; D015684:Gene Products, pol / Q000276:immunology; D007111:Immunity, Cellular; D007371:Interferon-gamma / Q000276:immunology; D008253:Macaca mulatta; D018449:SAIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control*; D015302:Simian Immunodeficiency Virus / Q000276:immunology / Q000472:pathogenicity* / Q000502:physiology; D019562:Viral Load; D014779:Virus Replication
chemical_list: D015683:Gene Products, gag; D015693:Gene Products, nef; D015684:Gene Products, pol; D018449:SAIDS Vaccines; D007371:Interferon-gamma